Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/3101
|
| Title: | Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma |
| Authors: | Yuan, JN;Chao, Y;Lee, WP;Li, CP;Lee, RC;Chang, FY;Yen, SH;Lee, SD;Whang-Peng, J |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background To investigate the therapeutic index of combining etoposide, doxorubicin (adriamycin), cisplatin, 5-fluorouracil (5-FU), and leucovorin (EAPFL) chemotherapy in the treatment of advanced HCC, a trial of a novel schedule of triweekly administration was conducted. Patients and methods Sixty-six patients with measurable advanced HCC, adequate liver and renal functions and adequate bone marrow reserves in whom local treatment was not indicated were studied. Triweekly EAPFL treatment consisted of a concomitant boost of etoposide 40 mg/m(2) i.v. over 30 min on day 1, 2, and 3, doxorubicin 30 mg/m(2) i.v. over 30 min on day 1 to a backbone regimen, triweekly PFL chemotherapy with cisplatin 60 mg/m(2), 5-FU 1,200 mg/m(2), and leucovorin 120 mg/m(2) given simultaneously by a 72-h i.v. infusion. Response, survival, and toxicity were evaluated. Results One patient had complete response (1%) and thirteen patients had partial response (20%). The objective response rate was 21% (95% confidence interval 11-31%). The median overall survival and median time to progression were 8.9 months and 3.3 months, respectively. Major treatment toxicities (grade 3-4) were neutropenia (28%), anemia (11%), thrombocytopenia (7%), hepatotoxicity (5%), vomiting (2%), and diarrhea (2%). There was no treatment-related death. Conclusion Triweekly EAPFL chemotherapy is a moderately effective regimen with tolerable toxicities in the treatment of advanced HCC. |
| Keywords: | Oncology |
| Date: | 2008-06 |
| Relation: | Medical Oncology. 2008 Jun;25(2):201-206. |
| Link to: | http://dx.doi.org/10.1007/s12032-007-9013-3 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1357-0560&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000256028700014 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=48049120897 |
| Appears in Collections: | [彭汪嘉康(1996-2007)] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000256028700014.pdf | | 162Kb | Adobe PDF | 693 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
